Recipharm is expanding its Monts production center in France to manufacture the Moderna vaccine, creating 100 jobs, despite challenges in recruiting skilled talent. The decision to relocate production is driven by economic interests, environmental concerns, and a desire to strengthen national sovereignty in the face of global supply chain vulnerabilities highlighted by the Covid-19 pandemic. The SYMBIOSE project represents a significant investment in the future of French industry, aiming to balance relocation with securing critical supplies from various regions.